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Abstract: This study aims to evaluate the multidrug resistance (MDR) reversal activity by 
magnetic nanoparticles of Fe3O4 (MNPs-Fe3O4) and 5-bromotetrandrine (BrTet) MDR cell line 
K562/A02 solitarily or symphysially. The proliferation of K562 and K562/A02 cells and the 
cytotoxicity on peripheral blood mononuclear cells (PMBCs) were evaluated by MTT assay. 
Cellular accumulation of daunorubicin (DNR) was analyzed by flow cytometry. Real-time 
polymerase chain reaction and Western blotting analyses were performed to examine the mRNA 
and protein levels of mdr1, respectively. The results showed that the combination of MNPs-Fe3O4 
and BrTet with effective concentrations significantly increased cytotoxicity against MDR cell 
line K562/A02. Both BrTet and MNPs-Fe3O4 increased the intracellular DNR accumulation 
in the K562/A02 cell line, and downregulated the level of mdr1 gene and expression of 
P-glycoprotein. Furthermore, the combination did not have significant cytotoxicity in PMBCs. 
We propose that MNPs-Fe3O4 conjugated with DNR and BrTet probably have synergetic effects 
on MDR reversal.
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Introduction
Multidrug resistance (MDR), defined as being induced by one kind of drug which 
generates cross-tolerance to various anticancer drugs with different structures and 
mechanisms. This cross-tolerance was noted to be the most important mechanism 
of self-dependence in cytotoxic injury of chemotherapeutics, as well as a major 
reason for relapse or failure of chemotherapy during treatment for hematological 
malignancies. The mechanism which generates the MDR phenotype is complex.1 
Mechanisms include drug excretion, antiapoptosis, activity changes in drug-
metabolizing enzymes such as serum glutathione S epoxide transferase (GST), 
topoisomerase II (TOPO II), protein kinase C (PKC), and reinforcement of recovery 
from DNA injury. However the major mechanism in the mediation of MDR was 
P-glycoprotein (P-gp, P170), a kind of transmembrane glycoprotein.2 P-gp, a 
member of ATP-binding cassette (ABC) transporter superfamily, encoded by mdr1 
gene, mediated drug resistance to anthracycline, vinca alkaloids, etc, in the function 
of the lipophilic drug excretion pump and leading to a decrease in cytotoxic drug 
accumulation. Several patients with hematological malignancies, such as acute 
leukemia,3 non-Hodgkin’s lymphoma,4 which were sensitive to chemotherapy at the 
initial stage of morbidity, were detected showing a non- or hypo-expression of P-gp 
pretherapy, but an over expression of  P-gp after relapse. Some studies indicated that 
mdr1/P-gp had a close correlation in the prognosis of the outcome of chemotherapy. International Journal of Nanomedicine 2009:4 210
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Patients with mdr1 overexpression had shorter life span, 
and a higher recurrence rate. P-gp inhibitors can improve 
the curative effect of myelodysplastic syndrome with 
overexpressed P-gp.5 Therefore, the analysis of mdr1/P-gp 
could be considered an anticipation index for the outcome 
of hematological malignancies.
At present, only the first and second generation of 
P-gp inhibitors have been tested in clinic trials, but the 
therapeutic effects and adverse reactions experienced 
were not ideal. The unity of the reversal mechanism was 
an important factor that interfered in clinic utilization. 
In recent years, drugs packaged by liposome or multimer 
have been developed. This could change the character of 
such drugs by affecting tumor cells selectively, decreasing 
toxicity, and augmenting the MDR reversal effect.6–8 
Nanotechnology displayed feasible application perspec-
tives initially through improving administration routes of 
chemotherapeutics, which rivaled neutralization excretion 
drugs by tumor cells in order to increase the intracellular 
accumulation of drugs. Magnetite, possessing a magnetic 
positive charge group, was the essential component of the 
magnetic particle. The present understanding is that the 
magnetic compound of Fe3O4 could self-synthesize into 
tela, suggesting that Fe3O4 has an existence physically. This 
characteristic of Fe3O4 was the safeguard for using it as a 
safe hypotoxic carrier.9
Tetrandrine (Tet), a type of hypotoxic calcium channel 
antagonist,10 could inhibit P-gp overexpresssion through 
competing activation of PKC and mdr1, and had a better 
reversal effect for leukemia in vivo and in vitro. The Tet 
may reverse MDR through downregulating the expression 
of mdr1mRNA or P-gp, increasing drug accumulation 
intracellularly, as well as reinforcing apoptosis induced by 
anticancer drugs. 5-bromotetrandrine (BrTet), a bromized 
derivative of Tet, has been shown to be more potent than 
Tet in the modulation of MDR.11 In the prophase trial, we 
applied magnetic nanoparticles of Fe3O4 (MNPs-Fe3O4) and 
BrTet connected with adriamycin (ADM) respectively for 
MDR reversal, and indicated that both of the drugs could 
increase the reversal effect. However both of the drugs had 
different targets, and the complexity of MDR mechanism 
determined the effect of the synergy in MDR reversal.
Materials and methods
Main reagents
Adriamycin (Hisun Phamaceutical Co., Zhejiang, China) 
stock solution 3.68 mM and daunorubicin (DNR) (Main 
Luck Phamaceuticals Inc., Shenzheng, China) stock solution 
3.55 mM were prepared with 0.01 M phosphate-buffered 
saline (PBS, pH = 7.4). BrTet (Kanghong Phamaceuticals 
Inc., Chengdu, China) was also diluted with 0.01 M 
PBS (pH = 7.4). All reagents used in this trial were of 
analytical grade.
Cell culture
Human chronic myeloid leukemia in blast crisis cell line, 
K562, and its resistant cell line to ADM, K562/A02, were 
both cultured in a RPMI 1640 medium (Gibco/BRL, 
Gaithersburg, MD, USA) supplemented with 10% fetal 
calf serum (FCS) (Sijiqing, Hangzhou, China), 100 U/mL 
penicillin and 100 µg/mL streptomycin at 37 °C in a 
humidified atmosphere of 5% CO2, and passaged every two 
days. The resistant cell line was incubated in the presence 
of ADM (1 µg/mL) until at least three days before starting 
the experiments. Peripheral blood mononuclear cells 
(PBMCs) were assembled and separated from healthy cells, 
and then cultured in a RPMI 1640 medium supplemented 
with 15% FCS, 100 ng/mL granulocyte colony-stimulating 
factor (G-CSF)12 at 37 °C in a humidified atmosphere of 
5% CO2 for one week before the commencement of the 
experiments.
Cytotoxicity assay
The in vitro chemosensitivity was measured by 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) (Sigma Aldrich, St. Louis, MO, USA) assay. Tumor 
cells (1.5 × 106/mL) were suspended in 100 µL of culture 
medium on 96-well culture plate (Costar; Fisher Scientific, 
Hampton, NH, USA) per well. For determining the reversal 
effect of MNPs-Fe3O4, BrTet was used alone or symphysially 
in graded concentrations of DNR with or without the reversal 
agents added. The concentration of BrTet was 0.5 µM, which 
is half of the recommended reversal concentration according 
to Chen and colleagues.13 MNPs-Fe3O4, 0.1 (V/V), was 
conjugated with graded concentrations of DNR and kept at 
4 °C for 48 hours before being applied to the experiment.14 
PBMCs (2.0 × 105/mL) were also suspended in 100 µL of 
culture medium in 96-well culture plate per well using the 
same concentration. To determine the antiproliferative effect 
of BrTet or MNPs-Fe3O4, various concentrations of these 
two reagents in 100 µL dilute of the culture medium were 
added into every well. Meanwhile, RPMI 1640 medium 
was regarded as the bank control and cells without reagents 
were the negative control. The cells were then incubated 
for 48 hours at 37 °C, following which, MTT (0.5 mg/mL) 
20 µL were added to each well and cultured for an additional International Journal of Nanomedicine 2009:4 211
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four hours. The formazan was dissolved with 150 µL 
dimethyl sulfoxide (Sigma Aldrich) after blotting the culture 
medium. The plates were shaken lightly for 10 minutes, and 
the reduction of MTT was quantified by absorbance at a 
wavelength of 490 nm using a microplate reader (Model-550; 
Bio-Rad Laboratories, Hercules, CA, USA). The relative 
growth rates (RGR) of PMBCs, evaluating the antiprolifera-
tive effect of BrTet or MNPs-Fe3O4, were transformed into 
six bands according to Table 1.
Cellular accumulation of DNR
Cellular accumulation of DNR was analyzed by flow 
cytometry (FCM) assay. Briefly, both K562/A02 cells 
(1.5 × 106/mL) and PMBCs (2.0 × 105 mL) were exposed to 
2 µM DNR in the absence or presence of BrTet at 0.5 µM or 
MNPs-Fe3O4 at 0.1 (V/V) for 24 hours at 37 °C to determine 
the cytotoxicity of BrTet and MNPs-Fe3O4. The PMBCs were 
sieved and incubated with CD34-FITC for 15 minutes. After 
being washed by PBS three times, the cells were suspended 
by 400 µL PBS and determined by a FACS Calibur flow 
cytometry (Becton Dickinson, Franklin Lakes, NJ, USA) 
assay at excitation and emission wavelengths of 488 nm 
and 575 nm, respectively.
Western blotting of P-gp
As described before, K562/A02 cells (1.5 × 106/mL) 
were treated, harvested, and then lysed in a lysis buffer 
containing 25 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 5 mM EDTA, 5 mM EGTA, 10 mM NaF, 
1 mM PMSF, 0.5% NP-40, 10 µg/ml aprotinin, 10 µg/ml 
leupeptin, and 1 mM pepstatin for 15 minutes. The 150 µg 
of total protein was electrophoresesed on 10% SDS-
polyacrylamide gels, and transferred onto a nitrocellulose 
membrane. Nonspecific binding sites were blocked by 5% 
milk powder dissolved in Tris-buffered saline (TBS) at 
room temperature for one hour. The primary P-gp antibody 
was mouse monoclonal anti-human antibody (Neomarkers, 
Fremont, CA, USA). The secondary antibody was alkaline 
phosphatase-labeled rabbit-mouse IgG. Membranes were 
exposed in nitroblue tetrazolium chloride (NBT)/5-bromo- 
4-chloro-3-indoxylphosphate (BCIP) were used as color 
detection reagents. After normalization by the correspond-
ing expression of β-actin, the levels of P-gp protein expres-
sion were determined by densitometry scans (ECL system, 
Amersham, UK). Meanwhile, K562 cells without any 
reagents were negative controls.
Real time PCR analysis of mdr1 
mRNA expression
Total cellular RNA was extracted from K562/A02 cells with 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and quanti-
fied by 1.5% agarose gel. Each group contained RNA from 
the cells incubated with DNR (2 µM), MNPs-Fe3O4 (0.1 v/v) 
loaded with DNR (2 µM), DNR (2 µM) connected with BrTet 
(0.5 µM); MNPs-Fe3O4 (0.1 v/v) loaded with DNR (2 µM) 
and conjugated with BrTet (0.5 µM), respectively. K562/A02 
cells and K562 cells without reagents were regarded as posi-
tive and negative controls. The reverse transcription reactions 
were performed using TaKaRa RNA PCR Kit (avian myelo-
blastosis virus, version. 3.0; Dalian, Liaoning, China). The 
newly synthetic cDNA was amplified by SYBR Premix Ex 
TaqTm real-time polymerase chain reaction (PCR) (TaKaRa) 
at ABI 7300 Real-Time PCR system (Applied Biosystems, 
Foster City, CA, USA). Primers involved were the mdr1 
primers (forwards 5′-TTGTTTGCCACCACGATA-3′, 
reverse 5′-GAACCACTGCTTCGCTTT-3′) and the GAPDH 
primers (forwards 5′-TGAACGGGAAGCTCACTGG-3′, 
reverse 5′-TCCACCACCCTGTTGCTGTA-3′). The ampli-
fied PCR products were 274bp and 205bp for mdr1 and 
GAPDH, respectively. The conditions for real-time PCR 
were 50 °C for 20 minutes and 45 cycles of 95 °C for 
10 minutes, 94 °C for 15 seconds, 59 °C for 20 seconds, and 
72 °C for 30 seconds. The Ct of both mdr1 and GAPDH were 
detected after each cycle. The expression of mdr1 was given 
as follows: Ct = Ctmdr1 - CtGAPDH.
statistical analysis
Data was analyzed using the Statistical Package for Social 
Science (v. 15.0; SPSS Inc., Chicago, IL, USA). The 
significance of differences in the mean value between groups 
was analyzed using one-way ANOVA; P values 0.05 
were considered statistically significant.
Table 1 The RgR and cytotoxicity gradation of PMBCs incubated 
with BrTet or MNPs-Fe3O4 for 48 hours
Cytotoxicity gradation RGR (%)
Band 0 100
Band 1 75∼99
Band 2 50∼74
Band 3 25∼49
Band 4 1∼24
Band 5 0
Notes:   The RgR was calculated as follow: ODtest cells/ODnegative control × 100%.   The 
band 0 or 1 was qualified, band 2 should be evaluated with morphology, and band 
3∼5 was unqualified.23
Abbreviations: OD, optical density; PMBCs, peripheral blood mononuclear cells; 
RgR, relative growth rate.International Journal of Nanomedicine 2009:4 212
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Results
effect of cytotoxicity of BrTet or Fe3O4
The cytotoxicity of BrTet or MNPs-Fe3O4 in PBMCs was 
assayed by the MTT assay. The transformation of RGR 
and the cytotoxicity gradation were evaluated according to 
Table 1. The data in Table 2 clearly indicates that BrTet at 
0.25∼2 µM and MNPs-Fe3O4 at 0.025∼0.1 (V/V) did not 
generate significant cytotoxicity.
Cell survival
According to the MTT assay, the ability of BrTet or 
MNPs-Fe3O4 used alone or in conjunction to reverse DNR 
resistance was compared in K562/A02 cell line. BrTet and 
MNPs-Fe3O4 symphysially showed significant reversal 
effect on DNR resistance in the K562/A02 cell line, and its 
potency was greater than using BrTet and Fe3O4 alone. The 
inhibitory concentration at 50% (IC50) of DNR decreased 
from 32.33 ± 8.40 µM to 1.80 ± 0.30 µM (P  0.001) 
at the combination of BrTet 0.5 µM and MNPs-Fe3O4 
0.1 (V/V), while the values were down to 7.49 ± 0.85 µM 
and 4.25 ± 2.16 µM for Fe3O4 and BrTet, respectively 
(P  0.001). The fold reversals were 17.96 of the synergia 
compared with the 4.32 of MNPs-Fe3O4 and 7.61 of 
BrTet alone. In contrast, there were no significant differences 
between those in K562 cell line (Table 3).
Fluorescence intensity  
of endocellular DNR
After repeating the trial three times, at a wavelength of 
488 nm, DNR was excited to emit at 575 nm wavelength 
spontaneously where fluorescence intensity (FI) of intra-
cellular DNR could be recorded by FCM. The mean 
fluorescence intensity of K562/A02 cells preincubated 
with 2 µM DNR for 48 hours was 44.49 ± 2.57; with DNR-
Fe3O4, 117.54 ± 2.53; with DNR-BrTet, 140.61 ± 4.32; 
and with DNR-Fe3O4-BrTet, 117.34 ± 3.54. The differ-
ences were significant when compared with control group 
(P  0.001). Furthermore, the fluorescence intensity of 
intracellular DNR of PMBCs had no dramatic variations 
(Figures 1, 2).
expression of P-gp
The expression of P-gp determined by western blotting 
analysis was downregulated to some extent after treatment 
with DNR in the presence of MNPs-Fe3O4 or BrTet alone 
or in combination for 48 hours, compared with K562/A02 
blank group (P  0.05). But there were no significant 
differences between the DNR in company with BrTet 
group and the group of DNR loaded with MNPs-Fe3O4 and 
BrTet (P  0.05). The relative expression was calculated 
as follows: gradationP-gp/gradationβ-actin (Figure 3).
Mdr1 mRNA level
DNR in the absence or presence of MNPs-Fe3O4 or 
BrTet alone or in combination downregulated the mdr1 
mRNA levels. The mdr1 relative expression of K562/A02 
was 19.68, which was 3.23 times lower compared with 
K562 cells. The value of mdr1 expression was significantly 
Table 2 The cytotoxicity of BrTet or MNPs-Fe3O4 on PBMCs 
for 48 hours determined by MTT assay
Groups  OD
(mean ± SD)
RGR (%)  Cytotoxicity 
gradation
BrTet (µM)
  Control 1.218 ± 0.154 – –
  0.25 1.247 ± 0.111* 102.38 Band 0
  0.5 1.261 ± 0.079* 103.50 Band 0
  1 1.222 ± 0.104* 100.27 Band 0
  2 1.221 ± 0.195* 100.22 Band 0
MNPs-Fe3O4 (V/V)
  Control 0.763 ± 0.023 – –
  0.025 0.741 ± 0.033** 97.16 Band 1
  0.05 0.737 ± 0.045** 96.63 Band 1
  0.1 0.697 ± 0.075** 91.39 Band 1
  0.2 0.552 ± 0.028** 72.30 Band 2
Notes: *P  0.05, compared with control group;  **P  0.05, compared with control 
group.
Abbreviations: BrTet, 5-bromotetrandrine; MNPs-Fe3O4, magnetic nanoparticles 
of Fe3O4; OD, optical density; PBMCs, peripheral blood mononuclear cells; RgR, 
relative growth rate; sD, standard deviation.
Table 3 The cytotoxicity of BrTet or MNPs-Fe3O4 on K562/
A02 and K562 cells for 48 hours determined by MTT assay 
(mean ± sD)
Groups IC50 of DNR (µM)
  K562/A02 K562
DNR 32.33 ± 8.40 2.74 ± 0.19
DNR – Fe3O4 ( 0.1 V/V) 7.49 ± 0.85 (4.32)* 2.31 ± 0.27 (1.19)
DNR + BrTet (0.5 µM) 4.25 ± 2.16 (7.61)* 2.80 ± 0.27 (0.98)
DNR – Fe3O4 + BrTet 1.80 ± 0.30 (17.96)* 2.39 ± 0.20 (1.15)
Notes: The values in parentheses were FR calculated as follows: FR = IC50 DNR alone/ 
IC50 DNR + agent. *P  0.05, compared with DNR group.
Abbreviations: BrTet, 5-bromotetrandrine; DNR, daunorubicin; FR, fold reversal; 
IC50, inhibitory concentration at 50%; MNPs-Fe3O4, magnetic nanoparticles of Fe3O4; 
OD, optical density; PBMCs, peripheral blood mononuclear cells; RgR, relative growth 
rate; sD, standard deviation.International Journal of Nanomedicine 2009:4 213
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decreased to 12.2 and 10.12 in the cells pretreated with 
DNR and loaded with MNPs-Fe3O4 and the combination 
of MNPs-Fe3O4 and BrTet, respectively, while BrTet con-
nected with DNR showed a less significant amount of 
mdr1 compared with BrTet only. The values were 17.89 
(Figure 4).
Discussion
MDR is considered to be a major problem for clinical 
therapy related to hematological malignancies. Several 
calcium channel inhibitors, such as verapamil, nifedipine, 
azidopine, or tetrandrine, can inhibit the excretion of anti-
cancer drugs, thus overcome MDR,15–16 but the toxicity 
of these drugs constrains both their application and their 
therapeutic effect. BrTet, a modified production of Tet, sig-
nificantly reversed resistance to ADM in MCF-7/Dox cell 
line in vivo, and restrained tumor growth in athymic mice 
bearing cancer.17 In our former study, reversal effect of BrTet 
was more effective than that of Tet in K562/A02 cell line 
in vivo and in vitro.11 In this experiment, we also studied the 
Figure 1 Cellular accumulation of DNR in K562/A02 cells after treatment with different reversal agents for 24 hours. A) Incubated with 2 µM DNR; B) Incubated with 2 µM 
DNR loaded with MNPs-Fe3O4 (0.1 v/v); C) Incubated with 2 µM DNR in conjunction with BrTet (0.5 µM); D) Incubated with 2 µM DNR loaded with MNPs-Fe3O4 (0.1 v/v) 
synergia with BrTet (0.5 µM).
Abbreviations: DNR, daunorubicin; MNPs-Fe3O4, magnetic nanoparticles of Fe3O4.
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Figure 2 Intracellular accumulation of DNR in PMBCs after treated with different reversal agents for 24 hours. A) Incubated with 2 µM DNR; B) Incubated with 2 µM 
DNR loaded with MNPs-Fe3O4 (0.1 v/v); C) Incubated with 2 µM DNR in conjunction with BrTet (0.5 µM); D) Incubated with 2 µM DNR loaded with MNPs-Fe3O4 (0.1 v/v), 
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cytotoxicity of BrTet in PBMCs, and the results showed that 
it was a safe, hypotoxic reversal agent and did not increase 
the drug accumulation in PMBCs in vitro. Since toxicity 
constrains the application of reversal reagents, we degraded 
half concentrations of BrTet and synergia with MNPs-Fe3O4. 
The results clearly indicated that the reversal activity of 
BrTet combined with MNPs-Fe3O4 was significantly greater 
than that of BrTet or MNPs-Fe3O4 alone at the same dose 
in the K562/A02 cell line, This result provides a synergia 
administration route in MDR reversal.
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Using nanoparticle carriers polymerizing chemo-
  therapeutics in MDR reversal is an exploratory study. 
Delivery systems of therapeutic nanoparticles could prevent 
drug degradation, change pharmacokinetics, and/or alleviate 
intracellular drug accumulation and disposition.18 In phar-
macological studies, nanoparticle carriers could increase 
concentrations of anticancer drugs intracellularly, and 
retain certain drug accumulation after drug withdrawal.19 
Several papers have also reported increasing concentrations 
of anticancer drugs though different nanoparticles when 
combined with these drugs.20,21 In our previous study, we 
used MNPs-Fe3O4 loaded with ADM in MDR reversal, 
and this strategy may have a MDR reversal effect through 
increasing cellular accumulation of DNR and downregulat-
ing the expression of mdr1.14 The overexpression of P-gp 
is the major cause of MDR development. Suppression 
of the expression of P-gp at either a transcriptional or 
a translational level is a critical approach to overcome 
MDR. In this trial, we also performed experiments on the 
mechanism of MDR reversal. As a result, MNPs-Fe3O4 
combined with BrTet could significantly increase cellular 
accumulation, and downregulate the expression of P-gp, 
but this combination seemed to have a less obvious effect 
on inhibiting the mdr1 gene than that of MNPs-Fe3O4 
loaded with DNR. As shown in other studies, BrTet may 
reverse MDR by retaining the route of translation from 
mdr1 mRNA to P-gp,22 which was in concordance with our 
results. How does the combination have the most obvious 
reversal effect? The mechanism may have something to do 
with targeted delivery.11 Targeted deliveries include passive 
and active targeting, and the former enhances permeability 
and retention. We consider that MNPs-Fe3O4 increase the 
DNR accumulation and retention through passive targeting, 
which has synergy with BrTet inhibiting P-gp in order to 
decrease active excretion. Therefore, this synergy could 
significantly reverse MDR compared with using these 
two reagents alone. This theory requires a penetrating 
mechanism study and an in vitro study.
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